Afficher la notice abrégée

Comparative Influences Of Betablockers And Verapamil On Cardiac Outcomes In Hypertrophic Cardiomyopathy

dc.rights.licenseopenen_US
hal.structure.identifierIstituto di Ricovero e Cura a Carattere Scientifico [IRCCS]
dc.contributor.authorPINTO, Giuseppe
hal.structure.identifierIstituto di Ricovero e Cura a Carattere Scientifico [IRCCS]
dc.contributor.authorCHIARITO, Mauro
hal.structure.identifierHôpital Européen Georges Pompidou [APHP] [HEGP]
hal.structure.identifierParis-Centre de Recherche Cardiovasculaire [PARCC (UMR_S 970/ U970)]
dc.contributor.authorPUSCAS, Tania
hal.structure.identifierHôpital Européen Georges Pompidou [APHP] [HEGP]
dc.contributor.authorBACHER, Anne
hal.structure.identifierCentre Hospitalier Universitaire [Rennes]
hal.structure.identifierLaboratoire Traitement du Signal et de l'Image [LTSI]
hal.structure.identifierCentre d'Investigation Clinique [Rennes] [CIC]
dc.contributor.authorDONAL, Erwan
hal.structure.identifierCIC Bordeaux
hal.structure.identifierCentre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB]
dc.contributor.authorREANT, Patricia
hal.structure.identifierIstituto di Ricovero e Cura a Carattere Scientifico [IRCCS]
dc.contributor.authorCONDORELLI, Gianluigi
hal.structure.identifierHôpital Européen Georges Pompidou [APHP] [HEGP]
hal.structure.identifierParis-Centre de Recherche Cardiovasculaire [PARCC (UMR_S 970/ U970)]
dc.contributor.authorHAGÈGE, Albert
dc.date.accessioned2025-06-18T08:47:26Z
dc.date.available2025-06-18T08:47:26Z
dc.date.issued2024
dc.identifier.issn0002-9149en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206943
dc.description.abstractEnGuidelines recommend betablockers as first line therapy in symptomatic patients with hypertrophic cardiomyopathy and non-dihydropyridine calcium channel blockers, particularly verapamil, as the second line therapy, despite absence of comparison trials between those two drugs. Since deleterious effects of verapamil have been reported in this setting, the present analysis aimed to evaluate the prognostic impact of betablockers and verapamil in a cohort of patients with hypertrophic cardiomyopathy. From a nation-wide cohort of 1434 patients with a diagnosis of hypertrophic cardiomyopathy included in the French prospective observational REgistry of hypertrophic cardioMYopathy (REMY), we retrospectively analysed individuals with sarcomeric hypertrophic cardiomyopathy included in the three largest centers and treated either with betablockers or verapamil. Patients with a cardiac defibrillator or a pacemaker or who underwent a procedure of atrial fibrillation or septal ablation were excluded. The primary endpoint was the composite of cardiovascular death, hospitalization for heart failure and hospitalization for atrial fibrillation. Out of 600 hypertrophic cardiomyopathy patients, 544 (91%) were treated with betablockers and 56 (9%) with verapamil. At inclusion, the two groups were comparable concerning presence/amplitude of obstruction and sudden cardiac death risk factors. At up to 8-year follow-up (median 3.9 years, IQR 2.1-5.8) no significant differences were observed in the primary endpoint (132 [24%] vs. 10 [18%] under betablockers or verapamil respectively, HR=1.84, 95% CI=0.94-3.63). In conclusion, in a real-world cohort of low risk patients with hypertrophic cardiomyopathy, verapamil therapy was not associated with a higher incidence of adverse events compared to betablocker therapy.
dc.language.isoENen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc/
dc.subject.enHypertrophic cardiomyopathy
dc.subject.enbetablockers
dc.subject.enprognosis
dc.subject.enverapamil
dc.title.enComparative Influences Of Betablockers And Verapamil On Cardiac Outcomes In Hypertrophic Cardiomyopathy
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.amjcard.2024.10.029en_US
dc.subject.halSciences du Vivant [q-bio]/Ingénierie biomédicaleen_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologie/Cardiologie et système cardiovasculaireen_US
bordeaux.journalAmerican Journal of Cardiologyen_US
bordeaux.page9-15en_US
bordeaux.volume235en_US
bordeaux.hal.laboratoriesCentre de Recherche Cardio-Thoracique de Bordeaux (CRCTB) - U1045en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierhal-04778575
hal.version1
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=American%20Journal%20of%20Cardiology&rft.date=2024&rft.volume=235&rft.spage=9-15&rft.epage=9-15&rft.eissn=0002-9149&rft.issn=0002-9149&rft.au=PINTO,%20Giuseppe&CHIARITO,%20Mauro&PUSCAS,%20Tania&BACHER,%20Anne&DONAL,%20Erwan&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
Pinto et al. - 2024 - Comparative ...
Taille:
1.109Mo
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée